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We agree with Erlend Faltinsen and colleagues that standardised mean differences can be difficult to 
translate into clinical practice. As reported in the Cochrane handbook, the mean difference (or more 
correctly, difference in means) measures the absolute difference between the mean value in two 
groups and then estimates the average amount that the experimental intervention changes in the 
outcome compared with that of the control intervention. Mean difference can be used in meta-
analysis as a summary statistic only when outcome measurements in all studies are made on the 
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same scale. By contrast with standardised mean differences, the overall intervention effect can be 
difficult to interpret because it is reported in units of SD rather than in units of a specific rating scale. 
Although, in some circumstances, it is possible to transform the effect back to the units used in a 
specific study, the problem with standardised mean differences is that this method assumes that 
differences in SD between studies reflect differences in measurement scales and not real differences 
in variability among study populations. This assumption could be problematic in circumstances in 
which there might be real differences in variability between the participants in different studies (for 
instance, pragmatic vs explanatory studies). For this reason, we paid careful attention when we 
drafted the inclusion and exclusion criteria in the protocol of our review1,2 and selected only trials 
that were similar in design, population, and interventions to reduce heterogeneity and 
inconsistency.3 This selection led to the inevitable exclusion of several trials. Even though we did an 
extensive search for published and unpublished data and contacted all study authors and 
pharmaceutical companies for additional data, we might, as is typically the case in systematic 
reviews, have missed some relevant studies. However, we do not agree that we should have 
included all the studies in the 2015 Cochrane review.4 Before finalising our list of included studies, 
we screened existing systematic reviews for any relevant reference in their lists of included (and 
excluded) studies. As detailed in the appendix of our review, we had to exclude several studies that 
were included by Ole Jakob Storebø and colleagues:4 51 studies with less than 7 days of treatment, 
38 crossover studies without washout period and no pre-crossover data (even after contacting the 
authors), 18 studies in which patients were responders to previous treatment, 14 studies where 
treatment was not as monotherapy, and a range of other studies without appropriate 
randomisation, with single-blind design, that included preschool children, or that administered non-
oral formulation of the investigational drug. Including these trials would have been a clear violation 
of our published protocol and a material risk for the transitivity of the network.3  
As prespecified in our peer-reviewed protocol,1,2 tolerability (proportion of patients who dropped 
out of studies because of side-effects) was chosen as primary outcome because it is consistently 
reported across studies and it is a hard outcome used in other similar reviews.5 We also analysed all-
cause discontinuation as a pre-defined secondary outcome. It is an important measure of treatment 
acceptability and full results are reported in the main text of our review and in the online appendix. 
We did not include edivoxetine because, when we drafted the protocol, we focused only on the 
drugs that were licensed or mentioned in international clinical guidelines at the time. We agree with 
Shuai Wang and Yi Zheng that systematic reviews should be as comprehensive as possible. We are 
aware that many new drugs for attention deficit hyperactivity disorder (ADHD) will be on the market 
in the near future. As we did with another network meta-analysis,6 we plan to publish the update of 
this review in a few years’ time and will include in the network, as appropriate, all the relevant 
medications that will be available at that time. 
In our network meta-analysis, we summarised the best available evidence about efficacy and 
acceptability of ADHD medications. In the protocol, we planned analyses of clinical outcomes at 
different time-points (acute and long term) but, unfortunately, there are not enough randomised 
controlled trials in the field. More long-term data and higher quality studies are urgently needed. 
We totally agree with John Warren that it is important to consider reliable information also about 
safety and harms when choosing a pharmacological treatment for ADHD (of course, this applies to 
any intervention in any disorder in any field of medicine). We are working on this question and have 
almost completed the data collection for a parallel project (based on the same protocol), which 
investigates the profile of specific adverse events for each drug, including—among others—
psychotic symptoms, suicidality, sleep problems, headache, loss of appetite, and tics. 
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This information about tolerability will complete the clinical picture of the safety profile of ADHD 
medications and will better inform patients, carers, clinicians, and treatment guidelines. 
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